Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tandem Diabetes Care (TNDM) Invested Capital (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Invested Capital readings, the most recent being $155.2 million for Q4 2025.

  • On a quarterly basis, Invested Capital fell 48.92% to $155.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $155.2 million, a 48.92% decrease, with the full-year FY2025 number at $155.2 million, down 48.92% from a year prior.
  • Invested Capital hit $155.2 million in Q4 2025 for Tandem Diabetes Care, up from $133.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $449.6 million in Q2 2022 to a low of $133.0 million in Q3 2025.
  • Median Invested Capital over the past 5 years was $313.8 million (2023), compared with a mean of $312.2 million.
  • Biggest five-year swings in Invested Capital: soared 51.28% in 2021 and later crashed 52.22% in 2025.
  • Tandem Diabetes Care's Invested Capital stood at $433.1 million in 2021, then rose by 1.58% to $439.9 million in 2022, then decreased by 28.71% to $313.6 million in 2023, then fell by 3.15% to $303.8 million in 2024, then crashed by 48.92% to $155.2 million in 2025.
  • The last three reported values for Invested Capital were $155.2 million (Q4 2025), $133.0 million (Q3 2025), and $133.3 million (Q2 2025) per Business Quant data.